Skip to content

Esketamine: all studies

Page 84 of 123: studies 831 to 840 of 1,225, newest first. Back to the esketamine overview

Research

Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.

Frontiers in Medicine 2026 Hui Zhang, Yan An Jiang, Huajun Fu et al.

Postpartum depression (PPD) affects 10-20% of women after childbirth, with incidence reaching 30-50% in high-risk populations. Acute postoperative pain and sleep disturbance represent modifiable risk factors. This study evaluated whether a multimodal analgesic protocol combining dexmedetomidine and esketamine is associated with reduced PPD incidence in high-risk parturients undergoing cesarean...

DOI: 10.3389/fmed.2026.1828838 (opens in new tab) Full text (opens in new tab) Esketamine Cesarean delivery Dexmedetomidine High-risk parturients +3

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

General Hospital Psychiatry 2026 Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.

Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...

Digital Enablement of Psychedelic-Assisted Therapy in Non-Clinical Settings: A Systematic Review of Safety, Efficacy, and Implementation Models

Psychoactives December 24, 2025 Brendan Driscoll, Shaheen E. Lakhan 1 citation

Psychedelic-assisted therapy offers rapid and profound benefits for treatment-resistant psychiatric conditions but remains constrained by the need for intensive, clinic-based administration. Concurrently, advances in digital health technologies have introduced scalable tools. This systematic review evaluates the safety, efficacy, and implementation of digitally enabled psychedelic-assisted...

Ketamine infusion therapy for treatment-resistant major depressive disorder and suicidal ideation: Nursing care and considerations.

Nursing December 1, 2025 Rebecca Ann Ivory, Kathryn M. Pate, Brentyn M Jones et al.

Major depressive disorder (MDD) affects approximately 332 million people worldwide. Among those diagnosed with MDD, approximately 53% receive pharmacologic treatment, such as ketamine. Nurses must be knowledgeable about ketamine and other emerging, effective behavioral health therapies used to treat chronically depressed mood and acute suicidal ideation. This article outlines the best nursing...

Advances in ketamine therapy for multiple psychiatric disorders

Sichuan jingshen weisheng September 5, 2025 Zhang Kai, Cheng Zhaoyang, Wang Yuting

Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, has gained increasing attention for its rapid antidepressant effects in treatment-resistant depression (TRD) and suicidal ideation. Its mechanisms include NMDA receptor blockade, AMPA receptor activation, and upregulation of BDNF/mTOR signaling. Its enantiomers, esketamine and R-ketamine, as well as its metabolites,...

DOI: 10.11886/scjsws20250531003 (opens in new tab) Full text (opens in new tab) Esketamine Rapid antidepressant Nmda receptor Psychiatric disorders

Mechanism of antidepressant action of ketamine and differences between its two enantiomers.

Journal of Anesthesia and Translational Medicine September 1, 2025 Junbiao Zhan, Yuxi Zhang, Hao Tian et al.

Ketamine has been widely used since its discovery, and in addition to its anesthetic effects, in recent years it has been found to exhibit rapid and sustained antidepressant effects in rodent models and in patients with treatment-resistant depression (TRD) at subanesthetic doses. The antidepressant mechanism of ketamine has also been intensively studied, involving glutamate receptors such as...

Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system.

Psychiatry Research July 19, 2025 Kevin J Li, Natalie E Slama, Ingrid L Chen et al. 2 citations

Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...

Effects of ketamine on postoperative cognition: a scoping review.

British Journal of Anaesthesia July 7, 2025 Connor T A Brenna, Xuan W He, Daheng Liu et al. 8 citations

Postoperative delirium and other forms of perioperative neurocognitive deficits occur commonly in older adult patients. Ketamine, administered either before or during general anaesthesia, may have cognitive-sparing properties owing to its ability to reduce neuroinflammation, increase neurotrophin levels, or allow reductions in the doses of other general anaesthetic drugs. However, the efficacy...

DOI: 10.1016/j.bja.2025.05.035 (opens in new tab) Full text (opens in new tab) Arketamine Delayed neurocognitive recovery Perioperative neurocognitive disorders Postoperative delirium +3

Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 1, 2025 Altamura Mario, Leccisotti Ivana, Moretti Maria Claudia et al. 5 citations

Treatment-resistant depression (TRD) presents substantial clinical challenges, particularly in patients with Alzheimer's disease (AD) and older adults experiencing late-life depression. Traditional monoaminergic therapies often fail in this population due to neurodegenerative changes that impact receptor dynamics and neurotransmitter systems. Emerging evidence suggests that N-methyl-D-aspartate...

Measuring suicidal behavior in the era of rapid-acting antidepressants: A systematic review of ketamine studies.

Psychiatry Research June 1, 2025 Flávia Vieira, Ana Teresa Caliman-Fontes, Breno Souza-Marques et al.

Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically summarize and discuss the currently used instruments for assessing suicidal behavior in the context of ketamine and its enantiomers. We searched Medline/PubMed, Embase, and PsycINFO databases for ketamine (and its enantiomers) human studies exploring...